公开(公告)号：US20240398959A1

公开(公告)日：2024-12-05

申请号：US18642602

申请日：2024-04-22

Applicant: C4 THERAPEUTICS, INC.

Inventor： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Minsheng He ,  Kiel Lazarski ,  Gesine Kerstin Veits ,  Harit U. Vora

IPC: A61K47/54 ,  A61K31/45 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  C07D211/86 ,  C07D211/88 ,  C07D211/90 ,  C07D221/22 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D495/04 ,  C07D495/14 ,  C07D519/00 ,  C07K14/47 ,  C07K14/72

Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US12076405B2

公开(公告)日：2024-09-03

申请号：US17164446

申请日：2021-02-01

Applicant: C4 Therapeutics, Inc.

Inventor： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Mark E. Fitzgerald ,  Minsheng He ,  Ryan E. Michael

IPC: A61K47/54 ,  A61K31/4035 ,  A61K31/438 ,  A61K31/439 ,  A61K31/454 ,  A61K31/547 ,  A61K31/55 ,  C07D401/04 ,  C07D403/04

CPC classification number: A61K47/545 ,  A61K31/4035 ,  A61K31/438 ,  A61K31/439 ,  A61K31/454 ,  A61K31/547 ,  A61K31/55 ,  A61K47/554 ,  C07D403/04

Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US12049464B2

公开(公告)日：2024-07-30

申请号：US17901775

申请日：2022-09-01

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20230416251A1

公开(公告)日：2023-12-28

申请号：US18100992

申请日：2023-01-24

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Fabian Dey ,  Annick Goergler ,  Bernd Kuhn ,  Roger Norcross ,  Stephan Roever ,  Philipp Schmid

IPC: C07D471/10 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00

Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

公开(公告)号：US20230357180A1

公开(公告)日：2023-11-09

申请号：US18079815

申请日：2022-12-12

Applicant: C4 Therapeutics, Inc.

Inventor： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Minsheng He ,  Kiel Lazarski

IPC: C07D401/04 ,  C07D403/04 ,  C07D413/04

CPC classification number: C07D401/04 ,  C07D403/04 ,  C07D413/04

Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.

公开(公告)号：US20230279023A1

公开(公告)日：2023-09-07

申请号：US17959144

申请日：2022-10-03

Applicant: C4 Therapeutics, Inc.

Inventor： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Minsheng He ,  Martin Duplessis ,  Chi-Li Chen

IPC: C07D495/14 ,  C07D207/456 ,  C07D211/88 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  G07F17/32

CPC classification number: C07D495/14 ,  C07D207/456 ,  C07D211/88 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  G07F17/3211 ,  G07F17/3225 ,  G07F17/3244 ,  G07F17/3246 ,  G07F17/3272 ,  G07F17/3288

Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US11459335B2

公开(公告)日：2022-10-04

申请号：US16721650

申请日：2019-12-19

Applicant: C4 Therapeutics, Inc.

Inventor： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Minsheng He ,  Martin Duplessis ,  Chi-Li Chen

IPC: C07D495/14 ,  C07D207/456 ,  C07D211/88 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  A61K31/426 ,  A61K31/427

Abstract: This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation. The invention also provides Degrons that can be used to treat disorders mediated by cereblon or an Ikaros family protein, and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US12157735B2

公开(公告)日：2024-12-03

申请号：US17965569

申请日：2022-10-13

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US12048748B2

公开(公告)日：2024-07-30

申请号：US17524558

申请日：2021-11-11

Applicant: C4 Therapeutics, Inc.

Inventor： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Kiel Lazarski ,  Ryan E. Michael

IPC: A61K31/435 ,  A61K31/438 ,  A61K47/54 ,  C07D471/10 ,  C07D498/20 ,  C07D519/00

CPC classification number: A61K47/545 ,  A61K31/435 ,  A61K31/438 ,  A61K47/554 ,  C07D471/10 ,  C07D498/20 ,  C07D519/00

Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US20240076300A1

公开(公告)日：2024-03-07

申请号：US18144800

申请日：2023-05-08

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Martin Duplessis ,  Jae Young Ahn ,  Alexander W. Hird ,  Ryan E. Michael ,  Kiel Lazarski ,  Yanke Liang ,  Georg Jaeschke ,  Antonio Ricci ,  Annick Goergler ,  Daniel Rueher

IPC: C07D519/00 ,  A61K9/00 ,  A61K9/02 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  C07D487/04

CPC classification number: C07D519/00 ,  A61K9/009 ,  A61K9/02 ,  A61K9/08 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  C07D487/04

Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.